Bouso JC

Single-Dose Ayahuasca for Depressive and Anxiety Symptoms Associated With Cancer Diagnosis: A Single-Blind Feasibility Proof-of-Concept Trial.

Maekawa RM, Guerra LTL, Villanova B +8

Feasibility, safety and preliminary effects of ibogaine in patients with moderate and severe alcohol use disorder: a pilot, open-label study.

Rocha JM, Maekawa RM, Reis JAS +9

Classic psychedelics and personality: An updated systematic review.

Vicentini AB, de Paula CC, Silva Reis JA +3

Effects of ayahuasca on neuropsychological performance and social cognition: A systematic review.

de Paula CC, Vicentini AB, Guerra LTL +3

Personality, not cognition, distinguishes chronic ayahuasca and cannabis users from non-users.

Bouso JC, Andión O, Estévez SF +6

The Ibogaine Experience Scale (IES): Development and psychometric properties of a multidimensional measure of ibogaine's subjective effects.

González Espejito F, Esteban Rodríguez L, Pedrero Pérez EJ +7

A new insight into ayahuasca's adverse effects: Reanalysis and perspectives on its mediating role in mental health from the Global Ayahuasca Survey (GAS).

Andión Ó, Bouso JC, Sarris JJ +3

Corrigendum: Ayahuasca-induced personal death experiences: prevalence, characteristics, and impact on attitudes toward death, life, and the environment.

David J, Bouso JC, Kohek M +5

Effects of a Single Dose of Ayahuasca in College Students With Harmful Alcohol Use: A Single-blind, Feasibility, Proof-of-Concept Trial.

Rodrigues LS, Reis JAS, Rossi GN +9

Europe PMC2024

Long-term ayahuasca use is associated with preserved global cognitive function and improved memory: a cross-sectional study with ritual users.

Fonseca AM, Dos Santos RG, de Medeiros LS +10

Ayahuasca-induced personal death experiences: prevalence, characteristics, and impact on attitudes toward death, life, and the environment.

David J, Bouso JC, Kohek M +5

Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview.

Ona G, Reverte I, Rossi GN +4

ArticlePsychedelics

Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic.

Bouso JC, Révész D, Ona G +5

Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers: A Pilot, Proof-of-Concept, Feasibility, Randomized-Controlled Trial.

Rossi GN, Rocha JM, Osório FL +10

ArticlePsychedelics

Hallucinations and Hallucinogens: Psychopathology or Wisdom?

Bouso JC, Ona G, Kohek M +4

Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences.

Rodríguez-Cano BJ, Kohek M, Ona G +4

Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey.

Bouso JC, Andión Ó, Sarris JJ +5

Preliminary evidence of links between ayahuasca use and the corpus callosum.

Simonsson O, Bouso JC, Kurth F +4

ArticleDMT

Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate.

Jiménez JH, Bouso JC

Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof-of-concept, randomized, placebo-controlled trials.

Dos Santos RG, Rocha JM, Rossi GN +10

Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects.

Durante Í, Dos Santos RG, Bouso JC +1

Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study.

Révész D, Ona G, Rossi GN +5

The Shipibo Ceremonial Use of Ayahuasca to Promote Well-Being: An Observational Study.

Gonzalez D, Cantillo J, Perez I +6

Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial.

Rocha JM, Rossi GN, de Lima Osório F +7

Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies.

Rodrigues LS, Rossi GN, Rocha JM +4

Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey.

Perkins D, Schubert V, Simonová H +5

The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges.

Dos Santos RG, Bouso JC, Rocha JM +2

ArticlePsychedelics

Hallucinogens/psychedelics resurrected as new tools in psychiatric therapy.

Dos Santos RG, Bouso JC, Hallak JE

Psychedelic Medicines in Major Depression: Progress and Future Challenges.

Bouso JC, Ona G, Dos Santos RG +1

Polypharmacology or "Pharmacological Promiscuity" In Psychedelic Research: What Are We Missing?

Ona GS, Dos Santos RG, Hallak JEC +1

Europe PMC2020

Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review.

Ona G, Bouso JC

Europe PMC2020

Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination.

Jiménez-Garrido DF, Gómez-Sousa M, Ona G +4

Europe PMC2020

Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.

Dos Santos RG, Bouso JC, Hallak JEC

Europe PMC2019

Translational evidence for ayahuasca as an antidepressant: what's next?

Dos Santos RG, Bouso JC

Europe PMC2019

Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.

Rocha JM, Osório FL, Crippa JAS +4

Europe PMC2019

Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.

Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ +1

Europe PMC2018

Psychedelics and Personality.

Aixalà M, Dos Santos RG, Hallak JEC +1

Europe PMC2018

Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.

Dos Santos RG, Bouso JC, Hallak JEC

Europe PMC2017